With
this release, scientists can avoid several drawbacks faced with existing RNAi
tools.
Open Biosystems develops, manufactures and markets genomic research tools
to scientists in academic, government and industrial laboratories .

symposia interference

This whole genome RNAi offering extends
Open Biosystems' portfolio of genomic products, utilized by investigators
worldwide, in assigning function to disease-causing genes and delineating the
molecular networks in which they function.

peptide portals

ibc peptide

announced
today the imminent completion of its Expression Arrest (TM) Whole Genome human
short hairpin RNA (shRNA) library.

carlsbad genome

REDWOOD CITY, Calif.com

CONTACT: Troy Moore, Chief Technology Officer, 256-704-4848,
tm@openbiosystems.

biomanufacturing portals

m.

Gregory Hannon's laboratory at CSHL has pioneered efforts in
elucidating the role of RNAi in vivo and developing research tools for
applying RNAi technologies to drug development processes.

collaborations membrane

The webcast will be archived for 90 days
following the presentation. The Expression Arrest human genome shRNA library
will begin shipping by June 10th 2005 while the mouse whole genome shRNA
library will be completed by August 2005.

biotechnology biochemistry

Already adopted by many of the leading cancer centers worldwide, the
Expression Arrest shRNA libraries provide researchers immediate access to
ready-to-use RNAi triggers against the entire human and mouse genomes.
Troy Moore, Chief Technology Officer at Open Biosystems, said, "Expression
Arrest shRNA will enable researchers worldwide to unravel complex genetic
networks at their benchtop- greatly facilitating the validation of new drug
targets"
Created by Greg Hannon (CSHL) and Steve Elledge (Harvard), the Expression
Arrest human whole genome shRNA collection targets over 30,000 genes with
multiple shRNA constructs per gene and all protein classes including those
considered druggable targets.

collaborations aventis

, headquartered in Redwood City, California, is focused on
creating novel products using its integrated proprietary technologies for
human therapeutics.

interference carlsbad

oligonucleotide biotechnology

Additional features unique to Expression Arrest shRNA include built-in
molecular barcodes allowing rapid and large-scale RNAi screens, the ability to
effectively deliver into difficult-to-transfect cell lines , and greater gene
knockdowns due to the micro-RNA based design.

CONTACT: Cold Spring Harbor Technology Licensing, 516-367-6885.

membrane genomics

These
research tools provide investigators with standardized high-quality genes,
RNAi and antibodies for interrogating gene function in relation to oncology,
neuroscience and metabolic disorders.

shriram genome

com.

ibc peptide

(Nasdaq: MAXY) announced today that the company will present at the BIO CEO +
Investor Conference held at the Waldorf Astoria hotel in New York, NY.

portals microbiology

Maxygen, Inc.

cgmp interference

genome collaborations

Now scientists can use Expression Arrest shRNA to perform transient , stable,
and in vivo RNAi studies, unlike siRNA which allows transient-only studies.

About CSHL
CSHL is a research and education institution with research programs
focusing on cancer , neurobiology, plant genetics, genomics and bioinformatics,
and a broad educational mission, including the Watson School of Biological
Sciences. Dr.

shriram cgmp

To
access the live audio webcast, visit the "Investors " section of the company's
website at http://www.

collaborations interference

com. Maxygen's technologies bring together advances in
molecular biology and protein modification to create novel biotechnology
products. The most significant improvement is the added flexibility versus siRNA. For more information, visit Open
Biosystems ' website: http://www.

biotechnology genome

Maxygen has strategic collaborations with leading companies
including Roche and Aventis.

About Open Biosystems, Inc.openbiosystems.

oligonucleotide membrane

The
presentation will begin at 11:00 a.maxygen.

interference portals

, Maxygen, Inc.

collaborations ibc

Maxygen Inc. Announces Webcast of Corporate Presentation at the BIO CEO + Investor Conference

(ET) on Thursday, February 24, 2005. HUNTSVILLE, Ala., Open Biosystems , Inc.

portals tartu

Complete Coverage of the Human Genome With 'microRNA Adapted' shRNA: Ready-to- Use Comprehensive RNA Interference (RNAi) Resource

bioethics chemotherapy

symposia membrane

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)